EUVIMEDEUVIMED entdecken
VergleichsstudieKohortenstudie

Comparison of Outcomes Between Protocolized Tacrolimus‐Based and Non‐Protocolized Ciclosporin‐Based Triple‐Combination Therapy in Interstitial Lung Disease With Anti‐MDA5‐Positive Dermatomyositis: A Single‐Center Retrospective Cohort Study

Risa Yamada, Masayoshi Harigai, Yasuhiro Katsumata iD

International Journal of Rheumatic Diseases · 2025-07 · 28 (7)

DOI: 10.1111/1756-185x.70353 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift International Journal of Rheumatic Diseases, online erschienen am 30.06.2025. Verfasst von Risa Yamada und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Rheumatology, Tokyo Women's Medical University School of Medicine, Tokyo, Japan. Hauptthemen laut MEDLINE: Dermatomyositis, Tacrolimus, Lung Diseases, Interstitial, Interferon-Induced Helicase, IFIH1. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 27 Literaturangaben. Gefördert von: JSPS KAKENHI.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aim

We retrospectively compared the outcomes of protocolized tacrolimus‐based and non‐protocolized ciclosporin‐based triple‐combination therapies in consecutive patients with newly diagnosed interstitial lung disease (ILD) and antimelanoma differentiation‐associated gene 5 (MDA5)‐positive dermatomyositis (DM).

Methods

Clinical data from consecutive adult patients with newly diagnosed anti‐MDA5‐positive DM‐associated ILD in our hospital from 2013 to 2022 were analyzed. Recent cases received protocolized therapy with high‐dose glucocorticoids (GCs), tacrolimus, and intravenous cyclophosphamide (IVCY). Earlier cases received non‐protocolized ciclosporin‐based triple‐combination therapy. The observation period was 12 months. The outcomes included a composite of death or requirement for long‐term domiciliary oxygen therapy (LTOT), mortality, GC and IVCY doses, and cytomegalovirus reactivation rates within 12 months.

Results

Protocolized therapy with tacrolimus ( n = 14) and non‐protocolized therapy with ciclosporin ( n = 10) groups had similar baseline characteristics. No deaths or LTOT were observed in the protocolized therapy with the tacrolimus group, whereas four patients in the non‐protocolized therapy with ciclosporin group experienced these outcomes (difference, 40 percentage points; 95% CI, 10 to 70; p = 0.020). The 12‐month mortality rates were not significantly different between the two groups ( p = 0.16). The protocolized therapy with the tacrolimus group had lower GC dosages at 6 months, more total cycles and cumulative doses of IVCY, and lower cytomegalovirus reactivation rates than the non‐protocolized therapy with the ciclosporin group ( p < 0.05).

Conclusions

Protocolized tacrolimus‐based triple‐combination therapy demonstrated better outcomes than non‐protocolized ciclosporin‐based triple‐combination therapy in patients with anti‐MDA5‐positive DM‐associated ILD. Reduced GC doses and more intensive IVCY use also presumably contributed to better outcomes in the protocolized therapy with the tacrolimus group.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DermatomyositisTacrolimusLung Diseases, InterstitialInterferon-Induced Helicase, IFIH1CyclosporineImmunosuppressive AgentsGlucocorticoidsHumansRetrospective StudiesFemaleMaleMiddle AgedTreatment OutcomeDrug Therapy, CombinationCyclophosphamideAdultAgedAutoantibodiesTime Factors

Stichwörter der Autor:innen

anti‐melanoma differentiation‐associated gene 5 antibodydermatomyositisinterstitial lung diseaseoutcomestacrolimus

Substanzen

TacrolimusInterferon-Induced Helicase, IFIH1CyclosporineImmunosuppressive AgentsIFIH1 protein, humanCyclophosphamideAutoantibodiesGlucocorticoids

Autor:innen und Institutionen

  • Department of Rheumatology, Tokyo Women's Medical University School of Medicine, Tokyo, Japan.

ORCID-Profile: Yasuhiro Katsumata

Förderung

  • JSPS KAKENHI

Zitieren

APA

Yamada, R., Harigai, M., & Katsumata, Y. (2025). Comparison of Outcomes Between Protocolized Tacrolimus‐Based and Non‐Protocolized Ciclosporin‐Based Triple‐Combination Therapy in Interstitial Lung Disease With Anti‐MDA5‐Positive Dermatomyositis: A Single‐Center Retrospective Cohort Study. International Journal of Rheumatic Diseases, 28(7). https://doi.org/10.1111/1756-185x.70353

Vancouver

Yamada R, Harigai M, Katsumata Y. Comparison of Outcomes Between Protocolized Tacrolimus‐Based and Non‐Protocolized Ciclosporin‐Based Triple‐Combination Therapy in Interstitial Lung Disease With Anti‐MDA5‐Positive Dermatomyositis: A Single‐Center Retrospective Cohort Study. International Journal of Rheumatic Diseases. 2025;28(7). doi:10.1111/1756-185x.70353

BibTeX
@article{Yamada2025,
  author = {Yamada, Risa and Harigai, Masayoshi and Katsumata, Yasuhiro},
  title = {Comparison of Outcomes Between Protocolized Tacrolimus‐Based and Non‐Protocolized Ciclosporin‐Based Triple‐Combination Therapy in Interstitial Lung Disease With Anti‐MDA5‐Positive Dermatomyositis: A Single‐Center Retrospective Cohort Study},
  journal = {International Journal of Rheumatic Diseases},
  year = {2025},
  volume = {28},
  number = {7},
  doi = {10.1111/1756-185x.70353}
}
Kostenlos starten →